7 Jan, 2021

Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy

Dan Brudzewsky, PhD Senior Field Applications Scientist - UK & Nordics Travis Yates, PhD Field Applications Scientist Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy Within recent years, the field of oncology has seen major advancements in regards to therapeutic options for patients. Immunotherapy, which relies on [...]

30 Oct, 2017

Refining neoantigen load

Tumor mutational burden (TMB) has now been established as a positive predictive biomarker of response to immune checkpoint inhibitors with more studies demonstrating correlations between the overall mutational landscape and clinical benefit ...

Go to Top